[1]谭小宁,朱克俭,蒋益兰,等.基于SDF-1/CXCR4信号轴研究肺复方对肺癌A549细胞侵袭能力的影响[J].中国中医药信息杂志,2020,27(9):58-62.[doi:10.3969/j.issn.1005-5304.202003132]
 TAN Xiaoning,ZHU Kejian,JIANG Yilan,et al.Effects of Feifufang on Lung Cancer A549 Cells Invasion Based on SDF-1/CXCR4 Axis[J].zhongguo zhongyiyao xinxi zazhi,2020,27(9):58-62.[doi:10.3969/j.issn.1005-5304.202003132]
点击复制

基于SDF-1/CXCR4信号轴研究肺复方对肺癌A549细胞侵袭能力的影响

参考文献/References:

[1] 王宁,刘硕,杨雷,等.2018全球癌症统计报告解读[J].肿瘤综合治疗电子杂志,2019,5(1):87-97.

[2] MILLER K D, SIEGEL R L, LIN C C, et al. Cancer treatment and survivorship statistics, 2016[J]. CA A Cancer Journal for Clinicians,2016,66(4):271-289.

[3] FANG T, LV H, LV G, et al. Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of livercancer[J]. Nat Commun,2018,9(1):191.

[4] GIL M, SESHADRI M, KOMOROWSKI M P, et al. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases[J]. Proc Natl Acad Sci USA,2013,110(14):E1291-E1300.

[5] YU T, WU Y Y, HELMAN J I, et al. CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway[J]. Molecular Cancer Research:MCR,2011,9(2):161-172.

[6] FUKUNAGA S, MAEDA K, NODA E, et al. Association between expressioni of vascuLar endothelial growth factor C, chemokine receptor CXCR4 and lymph node metastasis in colorectal cancer[J]. Oncology,2006,71(3):204-211.

[7] 黄争荣,林浩,林锦培,等.益胃化浊汤对肺癌患者化疗后免疫功能及细胞因子水平的影响[J].光明中医,2019,34(22):3390-3392.

[8] 封佳莉,李和根,周晓辉,等.中医药干预874例晚期非小细胞肺癌的生存分析[J].安徽中医药大学学报,2019,38(6):10-14.

[9] 蒋益兰,潘敏求,蔡美.肺复方治疗中晚期老年非小细胞肺癌多中心临床研究[J].北京中医药大学学报,2012,35(10):712-720.

[10] 侯公瑾,蒋益兰.肺复方联合化癥回生口服液对晚期老年非小细胞肺癌患者PFS及生存率的影响[J].中医药导报,2014,20(4):7-9.

[11] 章慧,沈慧芸,王亿君.肺复方对Lewis肺癌裸鼠移植瘤的抑瘤作用及抗血管生成的机制研究[J].湖南师范大学学报(医学版),2015,12(6):111-114.

[12] ARVELO F, SOJO F, COTTE C. Tumour progression and metastasis[J]. Ecancermedical Science,2016,10:617.

[13] SELMA R F, ALFONSO S A, SILVANA P B, et al. Role of chemokines in nonsmall cell lung cancer:angiogenesis and inflammation[J]. J Cancer,2015,6(10):938-952.

[14] ZHU Q, LUO R, GU J, et al. High CXCR4 expression predicts a poor prognosis in resected lung adenosquamous carcinoma[J]. J Cancer,2020,11(4):810-818.

[15] SOBOLIK T, SU Y J, WELLS S, et al. CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways[J]. Mol Biol Cell,2014,25(5)566-582.

[16] XU W T, YANG Z, LU N H. A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition[J]. Cell Adh Migr,2015,9(4):317-324.

[17] ZHU W B, XIAO N, LIU X J. Dietary flavonoid tangeretin induces reprogramming of epithelial to mesenchymal transition in prostate cancer cells by targeting the PI3K/Akt/mTOR signaling pathway[J]. Oncol Lett,2018,15(1):433-440.

相似文献/References:

[1]曾柏荣,王理槐,孙银辉.扶正口服液对气阴两虚型Ⅲ-Ⅳ期肺癌患者化疗毒副反应的影响[J].中国中医药信息杂志,2013,20(12):73.[doi:10.3969/j.issn.1005-5304.2013.12.029]
 [J].zhongguo zhongyiyao xinxi zazhi,2013,20(9):73.[doi:10.3969/j.issn.1005-5304.2013.12.029]
[2]范宏宇.肺癌咯血的中医治疗[J].中国中医药信息杂志,2009,16(5):82.
 [J].zhongguo zhongyiyao xinxi zazhi,2009,16(9):82.
[3]王芬,周而复,陈文强,等.中晚期肺癌中医证候与患者生存质量关系的分析[J].中国中医药信息杂志,2007,14(2):21.
 WANG Fen,ZHOU Er-ful,CHEN Wen-qiang,et al.Analysis on the Correlation between the Principa1 Components of TCM Symptoms and the Quality of Life of the Middle-Advanced Stages Lung Caner Patients[J].zhongguo zhongyiyao xinxi zazhi,2007,14(9):21.
[4]王芳,花宝金,李丛煌.肺瘤平膏Ⅱ号合并化疗治疗非小细胞肺癌临床观察[J].中国中医药信息杂志,2009,16(9):53.
 [J].zhongguo zhongyiyao xinxi zazhi,2009,16(9):53.
[5]李道睿,张培彤,胡晓梅,等.300例中晚期原发性支气管肺癌血瘀证分布规律的调查研究[J].中国中医药信息杂志,2007,14(3):19.
 LI Dao-rui,ZHANG Pei-tong,HU Xiao-mei,et al.Investigation of Distributing Characteristics of Blood Stasis Syndrome on 300 Cases of Advanced Stage Lung Cancer Patiens[J].zhongguo zhongyiyao xinxi zazhi,2007,14(9):19.
[6]闫向勇,孟庆常,燕忠生,等.岩舒注射液对肺癌放射性肺损伤的保护作用[J].中国中医药信息杂志,2008,15(4):82.
 [J].zhongguo zhongyiyao xinxi zazhi,2008,15(9):82.
[7]樊春晓,崔蒙,于琦,等.基于中医药数据库的中医药治疗肺癌临床文献分析[J].中国中医药信息杂志,2011,18(5):27.[doi:10.3969/j.issn.1005-5304.2011.05.010]
 FAN Chun-xiao,CUI Meng,YU Qi,et al.Analysis on Clinical Literature of TCM for Lung Cancer in Recent Decade of Domestic Journals[J].zhongguo zhongyiyao xinxi zazhi,2011,18(9):27.[doi:10.3969/j.issn.1005-5304.2011.05.010]
[8]山广志,王海涛.黄枇烟吸入法治疗肺癌临床观察[J].中国中医药信息杂志,2011,18(8):77.[doi:10.3969/j.issn.1005-5304.2011.08.035]
[9]齐元富,李秀荣,李慧杰.大黄?虫丸治疗肺癌临床研究[J].中国中医药信息杂志,2011,18(11):15.[doi:10.3969/j.issn.1005-5304.2011.11.006]
 QI Yuan-fu,LI Xiu-rong,LI Hui-jie.Clinical Study on Lung Cancer Treated by Dahuang Zhechong Wan[J].zhongguo zhongyiyao xinxi zazhi,2011,18(9):15.[doi:10.3969/j.issn.1005-5304.2011.11.006]
[10]李丛煌,指导:花宝金.肺癌中医证候研究进展[J].中国中医药信息杂志,2007,14(8):95.
 [J].zhongguo zhongyiyao xinxi zazhi,2007,14(9):95.

备注/Memo

基金项目:国家自然科学基金(81503452、81803787);湖南省中医药研究院重点项目(201804)

更新日期/Last Update:

2020-08-20